Loading clinical trials...
Loading clinical trials...
A Phase I Open-label Dose Escalation Study of Single Oral Daily Doses of BIBW 2992 for Three Days After Administration of Docetaxel, in Patients With Advanced Solid Tumors
Conditions
Interventions
Docetaxel
BIBW 2992
Start Date
May 1, 2005
Primary Completion Date
March 1, 2008
Last Updated
June 24, 2014
NCT07169851
NCT07159659
NCT00026884
NCT07213804
NCT07191730
NCT06662786
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions